Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Hjorth

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Journal of Psychopharmacology (Oxford, England)|May 12, 2016
Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000)Stephan Hjorth
Frontiers in Psychiatry|December 13, 2021
The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology PerspectiveStephan Hjorth
The AAPS Journal|November 7, 2015
Pattern Recognition in Pharmacodynamic Data AnalysisJohan Gabrielsson, Stephan Hjorth
Pharmacological Reviews|January 10, 2023
Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and ClearanceJohan Gabrielsson, Stephan Hjorth
Frontiers in Psychiatry|June 6, 2022
Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective DisorderMats Bogren, Monica Soltesz, Stephan Hjorth
Journal of Pharmacokinetics and Pharmacodynamics|November 13, 2014
Modeling energy intake by adding homeostatic feedback and drug interventionPeter Gennemark, Stephan Hjorth, Johan Gabrielsson
Pharmacology & Therapeutics|October 13, 2017
In vivo potency revisited - Keep the target in sightJohan Gabrielsson, Lambertus A Peletier, Stephan Hjorth
Clinical Pharmacology and Therapeutics|April 11, 2020
Does In Vitro Potency Predict Clinically Efficacious Concentrations?Rasmus Jansson-Löfmark, Stephan Hjorth, Johan Gabrielsson
European Journal of Pharmacology|July 24, 2018
Lost in translation: What's in an EC<sub>50</sub>? Innovative PK/PD reasoning in the drug development contextJohan Gabrielsson, Lambertus A Peletier, Stephan Hjorth
Frontiers in Psychiatry|September 7, 2021
Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive DysfunctionJose Rodriguez Cruz, Johan Sahlsten Schölin, Stephan Hjorth
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Journal of Psychopharmacology (Oxford, England)|May 12, 2016
Looking back (and in)to the future: A personal reflection on 'Serotonin autoreceptor function and antidepressant drug action' (Hjorth et al., 2000)Stephan Hjorth
Frontiers in Psychiatry|December 13, 2021
The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology PerspectiveStephan Hjorth
The AAPS Journal|November 7, 2015
Pattern Recognition in Pharmacodynamic Data AnalysisJohan Gabrielsson, Stephan Hjorth
Pharmacological Reviews|January 10, 2023
Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and ClearanceJohan Gabrielsson, Stephan Hjorth
Frontiers in Psychiatry|June 6, 2022
Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective DisorderMats Bogren, Monica Soltesz, Stephan Hjorth
Journal of Pharmacokinetics and Pharmacodynamics|November 13, 2014
Modeling energy intake by adding homeostatic feedback and drug interventionPeter Gennemark, Stephan Hjorth, Johan Gabrielsson
Pharmacology & Therapeutics|October 13, 2017
In vivo potency revisited - Keep the target in sightJohan Gabrielsson, Lambertus A Peletier, Stephan Hjorth
Clinical Pharmacology and Therapeutics|April 11, 2020
Does In Vitro Potency Predict Clinically Efficacious Concentrations?Rasmus Jansson-Löfmark, Stephan Hjorth, Johan Gabrielsson
European Journal of Pharmacology|July 24, 2018
Lost in translation: What's in an EC<sub>50</sub>? Innovative PK/PD reasoning in the drug development contextJohan Gabrielsson, Lambertus A Peletier, Stephan Hjorth
Frontiers in Psychiatry|September 7, 2021
Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive DysfunctionJose Rodriguez Cruz, Johan Sahlsten Schölin, Stephan Hjorth
Pageof 4